Chelsea Therapeutics Reports FDA Acceptance of Northera NDA Resubmission, PDUFA Date Set at Feb. 14, 2014

Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP ) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission seeking approval to market NORTHERA™ (droxidopa), an orally active synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). The resubmission includes additional information to